↓ Skip to main content

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib

Overview of attention for article published in Gynecologic Oncology Research and Practice, May 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
Published in
Gynecologic Oncology Research and Practice, May 2016
DOI 10.1186/s40661-016-0026-5
Pubmed ID
Authors

Munetaka Takekuma, Kwong K. Wong, Robert L. Coleman

Abstract

Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a number of solid tumor including recurrent low-grade serous ovarian carcinoma (LGSOC). However, the long-term prognosis of patients who receive selumetinib, as well as the late toxicity of the agent, have not yet been described. In this case report, we present a patient with recurrent LGSOC with KRAS mutation whose tumor has not progressed and who has maintained a good general condition without severe toxicities following treatment with selumetinib for more than 7 years. Next generation sequencing of her tumor revealed a G12V mutation in KRAS. MAPK signaling inhibition plays a role in the biology of LGSOC. Although biomarkers have yet to definitively define patients with LGSOC who are likely to respond to therapy, exploration of specific alterations should be pursued in an excersie to develop a reliable companion diagnostic test.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 36%
Other 2 14%
Researcher 2 14%
Student > Ph. D. Student 2 14%
Student > Doctoral Student 1 7%
Other 1 7%
Unknown 1 7%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 8 57%
Medicine and Dentistry 2 14%
Agricultural and Biological Sciences 1 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Unknown 2 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2017.
All research outputs
#4,668,429
of 9,692,018 outputs
Outputs from Gynecologic Oncology Research and Practice
#10
of 23 outputs
Outputs of similar age
#116,915
of 263,576 outputs
Outputs of similar age from Gynecologic Oncology Research and Practice
#1
of 2 outputs
Altmetric has tracked 9,692,018 research outputs across all sources so far. This one has received more attention than most of these and is in the 50th percentile.
So far Altmetric has tracked 23 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one scored the same or higher as 13 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,576 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them